Fujian Pien Tze Huang
Fujian Pien Tze Huang is a Chinese traditional Chinese medicine and health-care brand centered on the Pien Tze Huang proprietary medicine and related pharmaceutical, personal-care, and wellness products.
Last updated October 9, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Fujian Pien Tze Huang is the consumer-facing identity associated with Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd., a Chinese pharmaceutical enterprise headquartered in Zhangzhou, Fujian. The brand is built around Pien Tze Huang, a proprietary traditional Chinese medicine product whose name is also used by the company and its wider product family. The company was established in 1999 and listed on the Shanghai Stock Exchange in 2003 under ticker 600436.SH. Its controlling shareholder is identified as Zhangzhou Jiulongjiang Group Co., Ltd., with ultimate control attributed to the Zhangzhou municipal state-owned assets authority. The core business is traditional Chinese medicine manufacturing. The flagship product family includes the original Pien Tze Huang preparation, Pien Tze Huang capsules, compound Pien Tze Huang lozenges, compound Pien Tze Huang ointment, and compound Pien Tze Huang hemorrhoid ointment. These products are marketed within the regulatory and commercial framework for Chinese proprietary medicines. Because formulations, indications, ingredients, and permitted claims can vary by product and jurisdiction, the brand should not be treated as a single standardized medicine or as a substitute for professional medical advice. Pien Tze Huang has also pursued a broader health-care strategy beyond its traditional medicine base. Company materials described a “one core, two wings” development approach introduced during the 2014 transformation period. The core was pharmaceutical manufacturing, including traditional Chinese medicine, while the two supporting businesses comprised cosmetics and daily-use products, including toothpaste, together with health foods and other health-related products. This strategy positioned the organization as a broader health and wellness group rather than a single-product medicine maker. The brand’s identity is closely connected to Chinese heritage, proprietary medicine, and the historical reputation of Zhangzhou as its home market. Its business model combines prescription- and pharmacy-oriented pharmaceutical products with consumer health and personal-care categories. The company has also been associated with investment activity and expansion across health-care-related businesses, although the supplied material does not establish a complete current list of subsidiaries, overseas markets, or retail channels. Corporate governance has been a notable part of the company’s public profile. Former chairman and Communist Party secretary Liu Jianshun left the chairmanship in 2021 after requesting early retirement for health reasons. In 2023, Zhangzhou disciplinary authorities announced that he had been expelled from the Communist Party and transferred for prosecution on allegations including serious disciplinary violations, abuse of office, illegal business activities, and suspected bribery. These allegations concern a former executive and should be distinguished from the brand’s products and ordinary operations. Fujian Pien Tze Huang remains an active Chinese traditional medicine and health-care brand. The available reference material is stronger on corporate structure, product families, leadership changes, and the 2014 strategic framework than on detailed founding history, international distribution, advertising campaigns, current executives, or independently verified product performance. Those areas require further source verification before being expanded.
History
Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. was established in 1999 in Zhangzhou, Fujian, and became a publicly traded company on the Shanghai Stock Exchange in 2003. The corporate identity developed around Pien Tze Huang, a proprietary traditional Chinese medicine product that gave the company its name and became its most recognizable commercial asset. The supplied material does not provide a verified account of the medicine’s original historical formulation or a named founder, so those details are not included here. The company’s early and continuing identity has been rooted in Chinese proprietary medicine manufacturing. Its principal product architecture expanded beyond a single dosage form to include Pien Tze Huang capsules and several compound products, including lozenges, topical ointment, and hemorrhoid ointment. This created a family-based brand structure in which the Pien Tze Huang name functions both as a flagship medicine name and as a wider corporate and consumer brand. A significant strategic shift was associated with 2014, when the company adopted a “one core, two wings” health-care development framework. Pharmaceutical manufacturing, including traditional Chinese medicine, remained the core business. The two additional areas were cosmetics and daily-use products, including toothpaste, and health foods and other health-related products. The approach sought to turn the company’s pharmaceutical heritage into a diversified health-care platform while retaining traditional medicine as its central competency. Liu Jianshun was chairman and Communist Party secretary from 2014 until his departure in 2021. Public reporting described the period as one in which the company promoted modernization, industrialization, and the broader health-care strategy. Liu requested early retirement in April 2021, citing health reasons. Pan Jie then became chairman, but resigned approximately eight months later; Lin Weiqi subsequently took over the chairmanship. The sequence made leadership continuity a visible corporate issue, although the supplied sources do not establish the complete later executive history. In August 2023, Zhangzhou disciplinary authorities announced disciplinary and legal action against Liu Jianshun. The announcement alleged serious violations involving political, organizational, integrity, and work-related rules; accepting gifts and substantial cash gifts; interfering in personnel appointments; operating businesses in violation of applicable rules; using official authority to benefit others; and allegedly accepting substantial property. Authorities stated that the matter involved suspected bribery and transferred it to prosecutors. The announcement also described the confiscation of alleged unlawful gains and related property. These are official allegations and disciplinary findings concerning a former executive, not a finding that the brand’s products themselves were unlawful. The company has continued to present itself as a pharmaceutical and health-care group with a core traditional Chinese medicine business and adjacent consumer categories. Reference material also records investments and acquisitions involving health-care funds, technology, and related companies, but the supplied extracts do not provide enough verified context to construct a complete corporate-development chronology. Current headquarters details beyond Zhangzhou, current leadership, exact overseas distribution, and a comprehensive product catalogue remain to be verified.
- 2023
Former chairman disciplinary case
[1]Zhangzhou authorities announced disciplinary expulsion and referral for prosecution of former chairman Liu Jianshun over alleged serious violations and suspected bribery.
- 2021
Chairmanship transition
[1]Liu Jianshun requested early retirement; Pan Jie became chairman, later resigning and being followed by Lin Weiqi.
- 2014
One core, two wings strategy
[1]The company introduced a broader health-care strategy retaining traditional Chinese medicine and pharmaceutical manufacturing as the core while developing cosmetics, daily-use products, health foods, and other wellness businesses.
- 2003
Shanghai Stock Exchange listing
[1]The company listed on the Shanghai Stock Exchange under ticker 600436.SH.
- 1999
Company established
[1]Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. was established in Zhangzhou, Fujian, creating the corporate platform associated with the Pien Tze Huang brand.
Products and positioning
A heritage-led Chinese traditional medicine and broader health-care brand, combining a proprietary core medicine with pharmaceutical, personal-care, health-food, and wellness offerings.
Traditional Chinese proprietary medicine
Pien Tze Huang
The flagship proprietary medicine and namesake of the company. It is the central product around which the brand’s pharmaceutical identity is organized. The supplied sources do not provide a sufficiently verified ingredient list, approved indications, dosage instructions, or formulation history, so those details are intentionally omitted.
Traditional Chinese proprietary medicine
Pien Tze Huang capsules
A capsule-format member of the Pien Tze Huang product family. It extends the core brand into an alternative dosage form within the company’s traditional Chinese medicine portfolio. Specific formulation, approval, and market-availability details are not established by the supplied references.
Traditional Chinese proprietary medicine
Compound Pien Tze Huang lozenges
A compound lozenge product carrying the Pien Tze Huang name. It represents the brand’s extension into orally administered consumer-oriented medicine formats. The available material identifies the product but does not substantiate its detailed medical claims or current distribution.
Topical pharmaceutical
Compound Pien Tze Huang ointment
A topical product in the compound Pien Tze Huang family. It demonstrates the brand’s expansion from an oral flagship medicine into external-use pharmaceutical preparations. Detailed approved uses, formulation data, and markets require confirmation from regulatory or company sources.
Topical pharmaceutical
Compound Pien Tze Huang hemorrhoid ointment
A hemorrhoid ointment sold under the compound Pien Tze Huang product family. It is part of the company’s broader traditional medicine and topical-care portfolio. No additional claims or performance assertions are made because they are not supported by the supplied references.
Controversies
2023
Disciplinary and bribery case involving former chairman Liu Jianshun
Zhangzhou disciplinary authorities announced that former chairman and Party secretary Liu Jianshun had been expelled from the Communist Party and that alleged criminal matters, including suspected bribery, were transferred to prosecutors. The announcement cited alleged acceptance of gifts and money, improper influence over appointments, prohibited business activity, abuse of office, and receipt of property in exchange for benefits.
Brand decisions
2014
Adoption of the one core, two wings health-care strategyStrategyBackground
The company sought to broaden its business beyond traditional Chinese medicine while preserving pharmaceutical manufacturing as its central capability.
Action taken
It defined traditional Chinese medicine and pharmaceutical manufacturing as the core, with cosmetics and daily-use products on one side and health foods and other health products on the other.
Aftermath
The framework became the stated basis for the company’s modernization, industrialization, and diversification into a broader health-care group.
Recent events
- 2021
Pien Tze Huang experienced a rapid succession of chairmen after Liu Jianshun's departure[1]
Leadership change
After Liu Jianshun requested early retirement, Pan Jie became chairman. Pan resigned about eight months later, and Lin Weiqi subsequently took the chairmanship.
Sources4 sources
- 1Former Pien Tze Huang chairman Liu Jianshun investigated and expelled from the Communist Partystcn.com
- 2Pien Tze Huang merger and investment activity databasestock.qianzhan.com
- 3Disciplinary and bribery case involving former chairman Liu Jianshunnbd.com.cn
- 4Disciplinary and bribery case involving former chairman Liu Jianshunnews.cnr.cn
Cite this profile: Cite the canonical profile. /brand-wiki/福建片仔癀 · Editorial policy · How profiles are compiled